OKYO Pharma (OKYO) lifts equity proceeds to $22M after option exercise

Rhea-AI Filing Summary

OKYO Pharma Limited reports that the underwriter has partially exercised its option to buy extra shares from the company in a recent equity offering. Piper Sandler & Co. purchased an additional 1,109,060 ordinary shares on March 12, 2026, lifting total gross proceeds from the underwritten public offering to approximately $22 million before fees and expenses. This follows the initial sale of 10,815,000 ordinary shares at $1.85 per share, all issued by the company under an effective Form F-3 shelf registration.

Insights

Capital markets analyst

OKYO completes equity raise with partial greenshoe exercise.

OKYO Pharma closed an underwritten offering of 10,815,000 ordinary shares at $1.85 per share, and the underwriter later exercised its option to buy 1,109,060 additional shares. This lifts total gross proceeds to about $22 million before fees.

The option exercise signals sufficient demand to place extra shares, and all shares were issued by the company, meaning the cash inflow goes directly to its balance sheet. The transaction used an effective Form F-3 registration with Piper Sandler & Co. acting as sole manager.

The eventual impact depends on how the new capital is deployed and the scale of dilution relative to total shares outstanding, which is not detailed in this excerpt. Future periodic reports may outline the use of proceeds and any resulting changes in liquidity or investment plans.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

March 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Partial Exercise of Option to Purchase Additional Shares

As previously announced on February 13, 2026, on February 12, 2026, OKYO Pharma Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. (the “Underwriter”), pursuant to which the Company issued and sold, in an underwritten public offering (the “Offering”) 10,815,000 ordinary shares, no par value, of the Company (“Ordinary Shares”), at a public offering price of $1.85 per share. The Offering closed on February 17, 2026. Pursuant to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,622,250 Ordinary Shares at the public offering price, less underwriting discounts and commissions.

Pursuant to the option, on March 12, 2026, the Underwriter purchased an additional 1,109,060 Ordinary Shares, bringing the total gross proceeds to the Company from the Offering to approximately $22 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. All of the Ordinary Shares sold in the Offering, including the additional shares, were offered by the Company.

Piper Sandler & Co. acted as sole manager for the Offering.

The Offering was made pursuant to the Company’s effective registration statement on Form F-3 (Registration No. 333-293145) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission on February 10, 2026, and a prospectus supplement thereunder, together with the accompanying prospectus included in the Registration Statement.

The information included in this report is hereby incorporated by reference into the Registration Statement and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: March 12, 2026	By:	/s/ Keeren Shah
		Keeren Shah
		Chief Financial Officer

FAQ

What did OKYO Pharma (OKYO) announce in this Form 6-K?

OKYO Pharma reported that its underwriter partially exercised an option to buy additional ordinary shares. Piper Sandler & Co. purchased 1,109,060 extra shares, increasing total gross proceeds from the recent underwritten public offering to approximately $22 million before fees and expenses.

How many OKYO Pharma shares were sold in the public offering and at what price?

OKYO Pharma sold 10,815,000 ordinary shares in an underwritten public offering at a public offering price of $1.85 per share. These shares, together with an additional 1,109,060 option shares, were all issued by the company under its effective Form F-3 registration statement.

What is the total gross proceeds raised by OKYO Pharma from the offering?

The company states that total gross proceeds from the underwritten public offering, including the partially exercised option shares, are approximately $22 million. This figure is before deducting underwriting discounts, commissions, and other offering expenses that OKYO Pharma is responsible for paying.

How did the underwriter’s option work in OKYO Pharma’s offering?

Under the underwriting agreement, Piper Sandler & Co. received a 30-day option to purchase up to 1,622,250 additional ordinary shares at the public offering price, less fees. On March 12, 2026, it exercised the option in part, buying 1,109,060 additional shares from OKYO Pharma.

Which bank managed OKYO Pharma’s underwritten offering and option exercise?

Piper Sandler & Co. acted as sole manager for OKYO Pharma’s underwritten public offering. It also served as underwriter for the 30-day option and purchased 1,109,060 additional ordinary shares upon partial exercise of that option on March 12, 2026.

Under what registration statement was OKYO Pharma’s offering conducted?

The offering was carried out under OKYO Pharma’s effective shelf registration statement on Form F-3, Registration No. 333-293145. The registration was declared effective by the SEC on February 10, 2026 and used together with a prospectus supplement for this transaction.